Inflammation  >>  fletikumab (NNC109-0012)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fletikumab (NNC109-0012) / Novo Nordisk
NCT00818064: Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis

Completed
1
32
Europe
anti-IL-20, NN8226, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis, Healthy
01/10
01/10
NCT01038674: Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

Completed
1
16
Europe
anti-IL-20, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis
12/10
12/10
NCT01261767: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Terminated
1
55
US
anti-IL-20, placebo
Novo Nordisk A/S
Inflammation, Psoriasis
01/11
01/11

Download Options